Delenex closes series A round at CHF13.5 million
This article was originally published in Scrip
Delenex Therapeutics, the Swiss fragment company spun out of ESBATech in September 2009 when it was acquired by Alcon, has closed its series A round at CHF13.5 million (€10 million). The initial financing round involved leading venture capitalists SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. The funds will be used to finance the clinical development of programmes emerging from the company's single chain antibody fragment platform.